Journal
OPHTHALMIC SURGERY LASERS & IMAGING RETINA
Volume 47, Issue 11, Pages 1-18Publisher
SLACK INC
DOI: 10.3928/23258160-20161031-07
Keywords
-
Categories
Funding
- Genentech
- Regeneron Pharmaceuticals
- Acucela
- Alcon Laboratories
- Allergan
- GlaxoSmithKline
- Ophthotech Corporation
- Pfizer
- Roche
- ThromboGenics
- Del Mar Pharmaceuticals
- Chiltern International
- Neurotech Pharmaceuticals
- Xcovery
- Alimera Sciences
- Neurotech Pharmaceutical
Ask authors/readers for more resources
BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of 0.3 mg ranibizumab (Lucentis; Genentech, South San Francisco, CA) in eyes with persistent diabetic macular edema (DME) after recent, chronic, and frequent bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: Open-label, prospective study of 0.3 mg ranibizumab for eyes with persistent DME after bevacizumab. Thirty eyes randomized to a sustained group or a pro re nata (PRN) dosing group. RESULTS: The mean change in ETDRS best-corrected visual acuity from baseline to 1 year was +6.7 letters in the sustained group, +6.4 letters in the PRN group, and +6.5 letters overall. There was an overall mean reduction of 116 mu m from baseline central subfield thickness at 1 year, with -92 mu m and -127 mu m decreases in the sustained and PRN groups, respectively. Adverse events included two deaths; one patient with multiple cardiopulmonary comorbidities, myocardial infarction, stroke, osteomyelitis; and mild posterior subcapsular cataracts in two eyes. CONCLUSION: Ranibizumab 0.3 mg demonstrated improved visual and anatomic outcomes in patients with persistent DME following bevacizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available